Cytospire Therapeutics is a preclinical stage company, developing next generation gamma delta T cell engagers for the treatment of solid and haematological malignancies. The Company’s core technology drives potent activation of both tumor and blood resident gamma delta T cells and opens a path to safer and more efficacious targeting of well-validated tumor antigens that are intractable to CD3 T cell engagers.
